Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
In recent years, frequent occurrence of enrofloxacin residues in breeding snail (Babylonia areolate) has been a problem. To reveal the pharmacokinetic characteristics of enrofloxacin and its metabolites in B. areolate, and to design a rational dosing method and the rest period, we fed B. areolate with 20 mg·kg−1 of enrofloxacin mixture at water temperature of (24.5 ± 2.5) ° C, and then sampled at 0.17th, 0.25th, 0.5th, 1st, 2nd, 4th, 12th, 24th, 48th, 72nd, 120th, 168th, 240th and 360th hour after the dosing. Shimadzu 8050 LC-MS/MS was used to determine the drug concentration in the tissues in each period. The results show that the drug-time data applied to the non-atrial models in Gastropod muscle, proboscis (Including esophageal glands) and liver: the Cmax of enrofloxacin was 7.82, 10.5 and 31.47 mg·kg−1, respectively; the Cmax of ciprofloxacin (Metabolite) was 0.72, 0.89 and 1.21 mg·kg−1, respectively; the enrofloxacin tmax was 1, 4 and 4 h, respectively; the ciprofloxacin tmax was 4, 12 and 4 h, respectively; the enrofloxacin t1/2z was 38.22, 52.44 and 62.40 h, respectively; the ciprofloxacin t1/2z was 66.23, 33.11 and 27.06 h, respectively; the theoretical drug rest period was 16.94, 16.79 and 17.99 d, respectively. The results indicate that for all tissues, 20 mg·kg−1 of enrofloxacin mixture with the Cmax/MIC over 10 is suitable for the treatment of B. areolate disease caused by Vibrio harveyi (MIC, 0.45 mg·L−1). It is recommended that the drug rest period should not be less than 440.76 ℃·d and the dosing should be once every 2 d, a total of 3 times.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Comments on this article